Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) saw a downside of -3.70% to close Tuesday at $9.36 after subtracting -$0.36 on the day. The 5-day average trading volume is 3,037,220 shares of the company’s common stock. It has gained $9.98 in the past week and touched a new high 2 times within the past 5 days. An average of 2,326,375 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,109,318.
IRWD’s 1-month performance is -12.93% or -$1.27 on its low of $9.22 reached on 08/22/23. The company’s shares have touched a 52-week low of $9.52 and high of $12.66, with the stock’s rally to the 52-week high happening on 01/06/23. YTD, IRWD has lost -24.46% or -$3.03 and has reached a new high 3 times. However, the current price is down -26.07% from the 52-week high price.
Insider Transactions
IRWD stock investors last saw insider trading activity on Aug 14.John Minardo (Chief Legal Officer) most recently sold 7,045 shares at $10.04 per share on Aug 14. This transaction cost the insider $70,732. Principal Accounting Officer, Silver Ronald, sold 1,976 shares at a price of $10.04 on Aug 14. Then, on May 30, Chief Executive Officer MCCOURT Thomas A sold 26,632 shares at a price of $10.70 per share. This transaction amounted to $284,962.
Valuation Metrics
IRWD stock has a beta of 0.96. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.31.
Ironwood Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 1.00, with the current ratio over the same period at 1.00. The trailing 12-month EBITDA margin is 61.31%. The firm’s gross profit as reported stood at $410.6 million against revenue of $410.6 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 103.49% to -$1.06 billion, while revenue of $45.71 million was 104.3% off the previous quarter. Analysts expected IRWD to announce $0.25 per share in earnings in its latest quarter, but it posted -$6.71, representing a -2,784.00% surprise. EBITDA for the quarter stood at more than -$1.08 billion. IRWD stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 950.0 million, with total debt at $815.75 million. Shareholders hold equity totaling $156.03 million.
Let’s look briefly at Ironwood Pharmaceuticals Inc. (IRWD) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 31.23% to suggest the stock is trending Neutral, with historical volatility in this time period at 37.27%.
The stock’s 5-day moving average is $9.69, reflecting a -5.07% or -$0.50 change from its current price. IRWD is currently trading -11.20% above its 20-day SMA, -11.70% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -18.04% and SMA200 by-14.60%.
Stochastic %K and %D was 13.18% and 13.24% and the average true range (ATR) pointed at 0.36. The RSI (14) points at 34.35%, while the 14-day stochastic is at 6.29% with the period’s ATR at 0.34. The stock’s 9-day MACD Oscillator is pointing at -0.11 and -0.43 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), CapitalOne launched coverage with an Overweight rating.
